Drugs / RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR
RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04129775 | Oct 2019 → Sep 2022 | sensorineural hearing loss disorder | Otonomy, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594583 ↗ |
| Known as | OTO-413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04129775 ↗ |
| Known as | OTO-413 (BDNF) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594583 ↗ |
| Known as | R-met-hu-bdnf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594583 ↗ |
| Known as | Recombinant methionyl human bdnf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594583 ↗ |
| Route | Other | “Single intratympanic injection” NCT04129775 ↗ |